GLP-1 아날로그 시장은 예측 기간 중(2024-2032년) CAGR 28%의 급격한 성장이 예상됩니다. 약물전달의 새로운 방법을 사용할 수 있게 되면서 이러한 약물의 채용을 증가시키고 있습니다.
2023년 6월 12일 미국과 캐나다 이외에서는 MSD로 알려진 Merck(NYSE:MRK)는 6월 21일부터 24일까지 개최되는 유럽 간 학회(EASL) 연차 총회에서 임상시험 중 GLP-1/글루카곤 수용체 핵심효과인 efinopegdutide(MK-6024)의 새로운 지견이 구두발표용으로 수리되었다고 발표했습니다.
적응증에 따라 시장은 듀라글루티드(Trulicity), 엑세나티드(Bydureon, Byetta), 리라글루티드(Victoza, Saxenda), 세마글루티드(Ozempic, Wegovy, Rybelsus), 틸제파티드(Mounjaro, Zepbound)로 구분됩니다. 또한 각 회사는 적응 확대에의 접근, 마케팅 시책의 강화, 딜리버리 시스템에 의한 컴플라이언스의 철저 등에 주력하고 있습니다. Pharmaceutical Industries Ltd.의 미국 계열사인 Teva Pharmaceuticals, Inc.(NYSE and TASE: TEVA)는 미국에서 Victoza(R)1(릴라글루티드 주사제 1.8mg)의 인증된 제네릭의 발매를 발표했습니다.
시장은 용도별로 2형 당뇨병과 체중 감량으로 구분됩니다. 2023년 시장에서는 2형 당뇨병이 큰 점유율을 차지하고 있습니다. 관리하는 데 도움이 되는 릴라글루티드와 같은 GLP-1 아날로그가 필요합니다. 이러한 치료제는 전통적인 치료제보다 점진적으로 선호되고 있습니다. 의료 시설과의 제휴에 의해 액세스를 향상시키고 있습니다.
판매 채널을 기반으로 시장은 병원, 소매 약국, 온라인 약국으로 구분됩니다. 유통 확률에서 중요한 기능을 담당하며 사용자의 액세스 가능성과 수요에 초점을 맞추고 있습니다. 커버 범위는 제조 업체가 두 시장, 특히 도시와 농촌 지역에 액세스하는 데 도움이 수요를 더 높일 수 있습니다. 치료 계획의 준수율을 높이는 교육 및 지원 프로그램을 제공해야합니다.
GLP-1 아날로그 시장 도입에 대한 이해를 높이기 위해 시장은 북미(미국, 캐나다, 기타 북미), 유럽(독일, 프랑스, 영국, 스페인, 이탈리아, 기타 유럽), 아시아태평양(중국, 일본, 인도 및 기타 아시아태평양) 및 기타 지역 아시아의 태평양 지역은 예측 기간 중(2024-2032년)에 현저한 CAGR로 성장할 것으로 예상되고 있습니다. 요뇨 관리에 대한 사람들의 관심이 높아짐에 따라 중국, 인도, 일본 등 주요 지역에서 뛰어난 당뇨병 관리 솔루션의 성장을 추진하고 있습니다. 지역에 특화된 광고 방법 등을 통해 커버 범위를 확대하는 것 에 큰 관심을 기울이고 있습니다. 더 중요한 것은 규제 당국의 승인과 저렴한 가격 제품의 입수가 새로운 시장에 필수적이라는 것입니다. 헬스케어 유닛 입원 환자에 대한 도달범위와 컴플라이언스에 도움이 됩니다.
이 시장에서 사업을 전개하는 주요 기업으로는 Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co. 등이 있습니다.
GLP-1 (Glucagon-Like Peptide-1) receptors agonists are copies of the naturally occurring GLP-1 hormone that have been modified in some way to make it more effective in treatment. They have an important role in the treatment of type 2 diabetes and obesity as they stimulate the release of insulin, suppress glucagon, decelerate gastric emptying, and increase satiety. These drugs assist in glycemic control and allow for effective weight loss, the two effects being protective of the heart in diabetic patients.
The GLP-1 Analogues Market is expected to grow with a significant CAGR of 28% during the forecast period (2024-2032) due to type 2 diabetes and obesity have risen significantly over the recent past all over the world. Further, increasing the demand for weight loss solutions as well as expanding cardiovascular effectivity scope drive the market. The availability of new methods of drug delivery, especially including oral preparations and the development of long-acting analogues also increases the adoption of the drug. Furthermore, increased patient awareness levels and government promotion related to diabetes improve market access.
On June 12, 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24.
Based on the indication, the market is segmented into Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta), Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound). The Liraglutide (Victoza, Saxenda) held a significant share of the market in 2023. Liraglutide is an area's key driver of growth because it is a miscellaneous GLP-1 that is effective in the treatment of both type 2 diabetes and obesity with cardiovascular effects. The versatility of the product, which goes under the brand name Victoza for diabetes and Saxenda for obesity, means a wider market base. Moreover, companies concentrate on approaches to enlarging indications, enhancing marketing initiatives, and ensuring greater compliance through delivery systems. For instance, on June 24, 2024, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced the launch of an authorized generic of Victoza(R)1 (liraglutide injection 1.8mg), in the United States.
Based on application, the market is segmented into type 2 diabetes and weight loss. Type 2 diabetes held a significant share of the market in 2023. The increasing global incidence of type 2 diabetes leads to the need for more GLP-1 analogues such as liraglutide that help to manage blood sugar levels while promoting weight loss. Such drugs are progressively preferred with respect to conventional treatments for their multiple valued aspects. Moreover, companies are improving access by expanding into growth lots and partnering with healthcare facilities exerting pressure for early detection.
Based on the distribution channel, the market is segmented into hospitals, retail pharmacies, and online pharmacies. The retail pharmacies are expected to grow with a significant CAGR during the forecast period (2024-2032). Retail pharmacies have an important function in the probabilities of the distribution of GLP-1 analogues, focusing on accessibility and demand by users. Their coverage assists manufacturers in accessing the two markets, especially the urban and the rural areas, making the demand higher. It is required to establish ongoing relations with retail chains, raise awareness and provide training and support programs that would increase compliance with therapy regimens.
For a better understanding of the market adoption of GLP-1 Analogues, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is because of a growing incidence of diabetes, the growth of cities, and, lastly, the increase in health care costs. Adding to this, the increased concerns among people regarding proper diabetes management drive the growth of superior diabetes management solutions in key areas such as China, India, and Japan. Moreover, companies pay much attention to growing the coverage through mergers, acquisitions, joint ventures, and own production facilities as well as localized advertisement techniques. More importantly, the approval of regulators and the availability of low-cost products are essential for new markets. Further, the concerned e-health technologies and telemedicine are helping the healthcare unit inpatient reach and compliance in rural areas.
Some of the major players operating in the market include Novo Nordisk A/S, Lilly, Sanofi, AstraZeneca, Pfizer Inc., Boehringer Ingelheim International GmbH, Amgen Inc., ZEALAND PHARMA, Merck & Co., Inc., Hanmi Pharm.Co.,Ltd.